ASH 2022 | Phase II study of acalabrutinib plus RICE in R/R DLBCL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, reports on results from a Phase II trial (NCT03736616) assessing acalabrutinib plus RICE chemotherapy in transplant-eligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Acalabrutinib plus RICE was beneficial after three cycles of treatment with respect to overall response (OR) and complete response (CR) rates. Dr Patel also highlights that a high proportion of patients were subsequently able to undergo autologous stem cell transplantation (autoSCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BeiGene: Consultancy; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; Fate Therapeutics: Research Funding; Genetech/Roche: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy; Celgene: Consultancy, Research Funding, Speakers Bureau; CRISPR Therapeutics: Research Funding; ADC Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Aptevo Therapeutics: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; MEI Pharma: Consultancy, Research Funding; Kite pharma: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Morphosys: Consultancy; Nurix: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding, Speakers Bureau; Sunesis Pharmaceuticals: Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Trillium Therapuetics/Pfizer: Consultancy, Research Funding; Velos Bio: Research Funding; Xencor: Consultancy, Research Funding; Abbvie: Consultancy; Adaptive Biotechnologies: Research Funding.
